Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. ETF
  3. MPLT
MPLT logo

MPLT

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

MPLT News

Maplight and CVRx Executives Increase Stock Holdings

Feb 23 2026NASDAQ.COM

Aktis Oncology Launches $200 Million IPO with $100 Million Investment from Eli Lilly

Jan 09 2026renaissancecapital

MapLight Accelerates Phase 2 Trial Timelines for Schizophrenia and Autism Studies

Jan 09 2026Globenewswire

MapLight Therapeutics Receives FDA Fast Track Designation for ML-007C-MA in Alzheimer's Treatment

Jan 05 2026NASDAQ.COM

MapLight Receives FDA Fast Track Designation for ML-007C-MA in Alzheimer's Disease Psychosis

Jan 05 2026Globenewswire

MapLight Receives FDA Fast Track Designation for ML-007C-MA in Alzheimer's Disease Psychosis

Jan 05 2026Newsfilter

Aktis Oncology Files for IPO in the U.S. Targeting $346 Million in Funding

Dec 19 2025Newsfilter

MapLight Therapeutics and SandboxAQ Partner to Create Treatments for Central Nervous System Disorders

Dec 16 2025Yahoo Finance

SandboxAQ and MapLight Collaborate on $200M CNS Therapy Development

Dec 16 2025Globenewswire

SandboxAQ and MapLight Collaborate on CNS Therapies with Potential $200M in Milestones

Dec 16 2025Newsfilter

MapLight Therapeutics Raises $296.5 Million in IPO, Funding Secured Through 2027

Dec 04 2025Globenewswire

MapLight to Announce Schizophrenia Trial Findings in Second Half of 2026

Dec 04 2025NASDAQ.COM

Marvell Reports Impressive Q3 Earnings, Alongside American Eagle, Microchip Technology, Box, and Other Major Stocks Rising on Wednesday

Dec 03 2025Benzinga

IBM Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Friday

Nov 21 2025Benzinga

Leerink Partners Begins Coverage of MapLight Therapeutics with Outperform Rating and Sets Price Target at $30

Nov 21 2025Benzinga

Stifel Begins Coverage of MapLight Therapeutics with a Buy Rating and Sets Price Target at $28

Nov 21 2025Benzinga